Oramed Pharmaceuticals Inc expected to post a loss of 2 cents a share - Earnings Preview
17/03/2025 20:19
Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to show no change in quarterly revenue when it reports results on March 19 (estimated) for the period ending December 31 2024 LSEG's mean analyst estimate for Oramed Pharmaceuticals Inc is for a loss of 2 cents per share. The one available analyst rating on the shares is "hold". The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Oramed Pharmaceuticals Inc is $3.25, above its last closing price of $2.39. This summary was machine generated March 17 at 20:19 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results